Drugs / AK0406
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07432698 | Feb 2026 → Apr 2027 expected | — | Shanghai Ark Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK0406 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07432698 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT07432698 ↗ |